{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:37:54Z","timestamp":1792784274980,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016958","name":"National Institutes of Health Office of Research Infrastructure Programs","doi-asserted-by":"publisher","award":["R01 CA246130"],"award-info":[{"award-number":["R01 CA246130"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/01jdyfj45","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA246130"],"award-info":[{"award-number":["R01 CA246130"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-24-1-0957"],"award-info":[{"award-number":["HT9425-24-1-0957"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/03g2zjp07","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-25-1-0893"],"award-info":[{"award-number":["HT9425-25-1-0893"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/03g2zjp07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.molmed.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:08:04Z","timestamp":1789477684000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["hPSC models in cancer mechanisms and therapeutic discovery"],"prefix":"10.1016","author":[{"given":"Chih-Wei","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candise","family":"Tat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-597X","authenticated-orcid":false,"given":"Dung-Fang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.08.002_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.08.002_bb0010","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/cancers17132102","article-title":"Overcoming barriers in cancer biology research: current limitations and solutions","volume":"17","author":"Colonna","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2026.08.002_bb0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.08.002_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0025","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.08.002_bb0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13287-025-04826-0","article-title":"Addressing the challenges of immunogenicity, heterogeneity and tumorigenicity in the clinical translation of human embryonic stem cells","volume":"16","author":"Xia","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.molmed.2026.08.002_bb0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.molmed.2017.06.004","article-title":"Osteosarcoma: molecular pathogenesis and iPSC modeling","volume":"23","author":"Lin","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0045","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2017.07.004","article-title":"Li\u2013Fraumeni syndrome disease model: a platform to develop precision cancer therapy targeting oncogenic p53","volume":"38","author":"Zhou","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2026.08.002_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.trecan.2016.07.007","article-title":"Modeling cancer with pluripotent stem cells","volume":"2","author":"Gingold","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117857119","article-title":"Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies","volume":"119","author":"Tu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.08.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009971","article-title":"Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome","volume":"17","author":"Jewell","year":"2021","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molmed.2026.08.002_bb0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2015.02.045","article-title":"Modeling familial cancer with induced pluripotent stem cells","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0070","article-title":"Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation","volume":"11","author":"Liu","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2026.08.002_bb0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.stem.2016.04.013","article-title":"Induced pluripotent stem cells meet genome editing","volume":"18","author":"Hockemeyer","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"E11128","DOI":"10.1073\/pnas.1814044115","article-title":"Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.08.002_bb0085","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41467-023-37398-9","article-title":"Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation","volume":"14","author":"Xu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113927","article-title":"ALK upregulates POSTN and WNT signaling to drive neuroblastoma","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0095","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","article-title":"Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0100","doi-asserted-by":"crossref","first-page":"33628","DOI":"10.1073\/pnas.2011780117","article-title":"Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.08.002_bb0105","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.celrep.2013.05.036","article-title":"An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression","volume":"3","author":"Kim","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-019-0393-5","article-title":"Cancer cell reprogramming: a promising therapy converting malignancy to benignity","volume":"39","author":"Gong","year":"2019","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.molmed.2026.08.002_bb0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-22-0167","article-title":"Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia","volume":"4","author":"Kotini","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.molmed.2026.08.002_bb0120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nature08797","article-title":"Direct conversion of fibroblasts to functional neurons by defined factors","volume":"463","author":"Vierbuchen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.08.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau4292","article-title":"Direct reprogramming of fibroblasts into antigen-presenting dendritic cells","volume":"3","author":"Rosa","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.08.002_bb0135","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-22-0882","article-title":"Li\u2013Fraumeni syndrome\u2013associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death","volume":"13","author":"Choe","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.08.002_bb0140","article-title":"LncRNA H19 suppresses osteosarcomagenesis by regulating snoRNAs and DNA repair protein complexes","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2026.08.002_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fcell.2015.00015","article-title":"Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line","volume":"3","author":"Moore","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcae037","article-title":"Decoding the molecular symphony: interactions between the m6A and p53 signaling pathways in cancer","volume":"6","author":"Shoemaker","year":"2024","journal-title":"NAR Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12965","article-title":"The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids","volume":"54","author":"Kim","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.molmed.2026.08.002_bb0160","doi-asserted-by":"crossref","first-page":"20127","DOI":"10.1073\/pnas.1920521117","article-title":"Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells","volume":"117","author":"Susanto","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.08.002_bb0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12672-022-00498-x","article-title":"PTCH1-null induced pluripotent stem cells exclusively differentiate into immature ectodermal cells with large areas of medulloblastoma-like tissue","volume":"13","author":"Nagao","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2016.11.018","article-title":"Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease","volume":"20","author":"Chao","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.08.002_bb0180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.celrep.2015.09.019","article-title":"Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia","volume":"13","author":"Mulero-Navarro","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0185","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3390\/cancers15092594","article-title":"Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs)","volume":"15","author":"Telliam","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2026.08.002_bb0190","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/cells11040628","article-title":"Modeling Down syndrome myeloid leukemia by sequential introduction of GATA1 and STAG2 mutations in induced pluripotent stem cells with trisomy 21","volume":"11","author":"Barwe","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2026.08.002_bb0195","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.stem.2012.08.004","article-title":"Trisomy correction in Down syndrome induced pluripotent stem cells","volume":"11","author":"Li","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nbt.3178","article-title":"Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells","volume":"33","author":"Kotini","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0205","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-21-0508","article-title":"Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor\u2013mutant neoplasms","volume":"12","author":"Wheeler","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.08.002_bb0210","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/bloodadvances.2021006325","article-title":"Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs","volume":"6","author":"Asimomitis","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2026.08.002_bb0215","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/cells12242847","article-title":"Modeling RET-rearranged non-small cell lung cancer (NSCLC): generation of lung progenitor cells (LPCs) from patient-derived induced pluripotent stem cells (iPSCs)","volume":"12","author":"Marcoux","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2026.08.002_bb0220","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/ijc.33713","article-title":"Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression","volume":"149","author":"Miura","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0225","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nm.4355","article-title":"Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing","volume":"23","author":"Crespo","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-024-00537-6","article-title":"Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition","volume":"8","author":"Forster","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0235","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.stem.2021.03.022","article-title":"Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids","volume":"28","author":"Huang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.gde.2024.102301","article-title":"Decoding cancer etiology with cellular reprogramming","volume":"90","author":"Huang","year":"2025","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.molmed.2026.08.002_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2026.08.002_bb0255","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1182\/blood-2023-189132","article-title":"Phase I study of FT538 plus daratumumab for treatment of relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Maakaron","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.08.002_bb0260","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1182\/blood-2024-198684","article-title":"Safety and efficacy of FT522, a first-in-class multi-antigen targeted off-the-shelf iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed\/refractory B-cell lymphoma","volume":"144","author":"Bachanova","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.08.002_bb0265","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/JCO.2024.42.16_suppl.7023","article-title":"Interim results from the ELiPSE-1 study: a phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies","volume":"42","author":"Patel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1044707","article-title":"The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: a review","volume":"12","author":"Apfelbaum","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0275","first-page":"43","article-title":"Molecular variants and mutations in medulloblastoma","volume":"7","author":"Schroeder","year":"2014","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0280","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/s41596-024-00971-7","article-title":"Generating human bone marrow organoids for disease modeling and drug discovery","volume":"19","author":"Olijnik","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.molmed.2026.08.002_bb0285","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","article-title":"Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies","volume":"13","author":"Khan","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.08.002_bb0290","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.stem.2026.01.010","article-title":"comBO: a combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders","volume":"33","author":"Shen","year":"2026","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12195-024-00798-y","article-title":"Three-dimensional tumor models to study cancer stemness-mediated drug resistance","volume":"17","author":"Lamichhane","year":"2024","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.molmed.2026.08.002_bb0300","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cells14161278","article-title":"Cellular models of aging and senescence","volume":"14","author":"Kim","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2026.08.002_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41514-024-00161-5","article-title":"Strategies for modeling aging and age-related diseases","volume":"10","author":"Jothi","year":"2024","journal-title":"NPJ Aging"},{"key":"10.1016\/j.molmed.2026.08.002_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1559183","article-title":"Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies","volume":"13","author":"Bae","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0315","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13046-026-03694-7","article-title":"Human iPSC-derived and conventional cancer models in precision oncology: advancing patient-specific therapies from bench to bedside","volume":"45","author":"Pant","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.08.002_bb0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2026.08.002_bb0325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0330","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0335","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0340","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.08.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0355","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.08.002_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009462","article-title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","volume":"12","author":"Ullrich","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0365","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.molmed.2026.08.002_bb0370","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0375","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13425","article-title":"\u2018Off the shelf\u2019 immunotherapies: generation and application of pluripotent stem cell-derived immune cells","volume":"56","author":"Wang","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.molmed.2026.08.002_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66801-w","article-title":"Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial","volume":"16","author":"Iinuma","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0385","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s12276-025-01422-3","article-title":"Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0390","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","article-title":"Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques","volume":"42","author":"Hu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0395","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0400","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf045","article-title":"Efficient generation of human dendritic cells from induced pluripotent stem cell by introducing a feeder-free expansion step for hematopoietic progenitors","volume":"117","author":"Elahi","year":"2025","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0405","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","article-title":"Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells","volume":"6","author":"van der Stegen","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.molmed.2026.08.002_bb0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.stem.2024.10.004","article-title":"Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a\/GLP","volume":"32","author":"Jing","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0415","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41587-024-02360-7","article-title":"Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells","volume":"43","author":"Ng","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0420","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-024-01165-w","article-title":"Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2026.08.002_bb0425","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0430","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0435","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.2023020528","article-title":"Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8\u03b1\u03b2+ T cells targeting multiple myeloma","volume":"143","author":"Bae","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.08.002_bb0440","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0445","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0450","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0455","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0460","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt9932","article-title":"Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors","volume":"11","author":"Jiang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2026.08.002_bb0470","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70169","article-title":"FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy","volume":"29","author":"Eckstrom","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0475","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0480","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.08.002_bb0485","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0490","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0495","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0500","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41586-023-06950-4","article-title":"The nuclear factor ID3 endows macrophages with a potent anti-tumour activity","volume":"626","author":"Deng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.08.002_bb0505","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1038\/s41467-025-58289-1","article-title":"Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse","volume":"16","author":"Heras-Murillo","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0510","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.23.02585","article-title":"Dendritic cell-based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"van \u2018t Land","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002432","article-title":"In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models","volume":"9","author":"Oba","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003827","article-title":"Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling","volume":"10","author":"Makino","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.08.002_bb0525","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/s41598-022-07305-1","article-title":"Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro","volume":"12","author":"Maruoka","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0530","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.immuni.2025.08.001","article-title":"Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity","volume":"58","author":"Henriques-Oliveira","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.08.002_bb0535","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.stem.2025.12.017","article-title":"Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy","volume":"33","author":"Shah","year":"2026","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0540","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.stem.2024.09.017","article-title":"Assembloid models of cell-cell interaction to study tissue and disease biology","volume":"31","author":"Onesto","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2026.08.002_bb0545","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s42003-024-06419-8","article-title":"Subpopulations of fibroblasts derived from human iPS cells","volume":"7","author":"Kobayashi","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2026.08.002_bb0550","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.3390\/cancers12082302","article-title":"Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue","volume":"12","author":"Costales-Carrera","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2026.08.002_bb0555","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.stemcr.2018.04.007","article-title":"Automated deep learning-based system to identify endothelial cells derived from induced pluripotent stem cells","volume":"10","author":"Kusumoto","year":"2018","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70979-y","article-title":"Reproducible production and image-based quality evaluation of retinal pigment epithelium sheets from human induced pluripotent stem cells","volume":"10","author":"Ye","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111435","article-title":"An artificial intelligence optimized hepatic differentiation unveils NR5A2 and AP-1 transcriptional regulation in hepatic maturation","volume":"302","author":"Huo","year":"2026","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2026.08.002_bb0570","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1038\/s41467-025-59596-3","article-title":"Iterative transcription factor screening enables rapid generation of microglia-like cells from human iPSC","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.08.002_bb0575","article-title":"A combinatorial transcription factor screening platform for immune cell reprogramming","volume":"17","author":"Kurochkin","year":"2026","journal-title":"Cell Syst."},{"key":"10.1016\/j.molmed.2026.08.002_bb0580","article-title":"3D printing of living responsive materials and devices","volume":"30","author":"Liu","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.molmed.2026.08.002_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146393","article-title":"Construction of 3D in vitro models by bioprinting human pluripotent stem cells: challenges and opportunities","volume":"1723","author":"Salaris","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2026.08.002_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700175","article-title":"3D bioprinting human induced pluripotent stem cell constructs for in situ cell proliferation and successive multilineage differentiation","volume":"6","author":"Gu","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.molmed.2026.08.002_bb0595","article-title":"Creation of cardiac tissue exhibiting mechanical integration of spheroids using 3D bioprinting","volume":"125","author":"Ong","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.molmed.2026.08.002_bb0600","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/8\/2\/025017","article-title":"Accessible bioprinting: adaptation of a low-cost 3D-printer for precise cell placement and stem cell differentiation","volume":"8","author":"Reid","year":"2016","journal-title":"Biofabrication"},{"key":"10.1016\/j.molmed.2026.08.002_bb0605","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5082\/5\/1\/015013","article-title":"Development of a valve-based cell printer for the formation of human embryonic stem cell spheroid aggregates","volume":"5","author":"Faulkner-Jones","year":"2013","journal-title":"Biofabrication"},{"key":"10.1016\/j.molmed.2026.08.002_bb0610","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41598-017-00690-y","article-title":"Cartilage tissue engineering by the 3D bioprinting of iPS cells in a nanocellulose\/alginate bioink","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.08.002_bb0615","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/ph15060678","article-title":"Three-dimensional (3D) printing in cancer therapy and diagnostics: current status and future perspectives","volume":"15","author":"Safhi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.molmed.2026.08.002_bb0620","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3390\/cells10112823","article-title":"Cardiotoxicity of antineoplastic therapies and applications of induced pluripotent stem cell-derived cardiomyocytes","volume":"10","author":"Huang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2026.08.002_bb0625","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","article-title":"Three-dimensional cell culture: the missing link in drug discovery","volume":"18","author":"Breslin","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2026.08.002_bb0630","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41378-021-00277-8","article-title":"Tumor-on-a-chip: from bioinspired design to biomedical application","volume":"7","author":"Liu","year":"2021","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.molmed.2026.08.002_bb2005","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","article-title":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","volume":"12","author":"Strati","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2026.08.002_bb2010","first-page":"S3","article-title":"467 | Safety and efficacy of FT522, an off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor in relapsed\/refractory B-cell lymphoma","volume":"43","author":"Bachanova","year":"2026","journal-title":"Hematol. Oncol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:14:10Z","timestamp":1789848850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":127,"alternative-id":["S1471491426001991"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.08.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"hPSC models in cancer mechanisms and therapeutic discovery","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}